Diarrhea News and Research

Latest Diarrhea News and Research

FDA grants full approval of SYNRIBO for injection

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has granted full approval of SYNRIBO (omacetaxine mepesuccinate) for injection. This oncology portfolio product received an accelerated approval in October, 2012 with additional clinical trial data required to fulfill post marketing requirements set forth by the FDA.

13 Feb 2014

Researchers offer new options for men whose prostate cancer has spread to bones

Dartmouth-Hitchcock Norris Cotton Cancer Center has treated three men with a recently FDA-approved treatment, which offers new options for men whose prostate cancer has spread to their bones.

13 Feb 2014

Alba Therapeutics reports positive results from Phase IIb trial of larazotide acetate for CeD treatment

Alba Therapeutics Corporation announced today the positive results of their Phase IIb trial evaluating its investigational product, larazotide acetate, a first-in-class tight junction regulator, intended for the treatment of patients with celiac disease (CeD).

11 Feb 2014

Zoetis reports revenue of $1.25 billion for Q4 2013

Zoetis Inc. today reported its financial results for the fourth quarter and full year 2013. The company reported revenue of $1.25 billion for the fourth quarter of 2013, an increase of 7% from the fourth quarter of 2012. Revenue reflected an operational increase of 9%, with foreign currency having a negative impact of 2 percentage points.

11 Feb 2014

Mallinckrodt announces commercial launch of PENNSAID

Mallinckrodt today announced the commercial launch of PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%). PENNSAID 2% is a topical non-steroidal anti-inflammatory drug (NSAID) approved for use in the treatment of the pain of osteoarthritis of the knees.

10 Feb 2014

Sarepta Therapeutics reports positive safety results from AVI-7288 Phase I study

Sarepta Therapeutics, Inc., a developer of innovative RNA-based therapeutics, today announced positive safety results from a Phase I multiple ascending dose study of AVI-7288 in healthy volunteers.

10 Feb 2014

Rice, UTMB develop diagnostic test for cryptosporidiosis

Bioengineers at Rice University and the University of Texas Medical Branch (UTMB) at Galveston have developed a simple, highly sensitive and efficient test for the diarrheal disease cryptosporidiosis that could have great impact on global health.

7 Feb 2014

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Pfizer Inc. announced today that it has agreed with Merck & Co., Inc., known as MSD outside the United States and Canada ("Merck"), through two Merck subsidiaries, to explore the therapeutic potential of Merck's investigational anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets.

5 Feb 2014

Furiex announces top-line results of Phase III clinical trials of eluxadoline in treatment of IBS-d

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced top-line results indicating the company's two pivotal Phase III clinical trials evaluating the efficacy and safety of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-d) met both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) formally agreed-upon primary endpoints of composite response based on simultaneous improvements in stool consistency and abdominal pain.

4 Feb 2014

Researchers develop rehydration beverage to treat hypohydration in astronauts

How is living in space like playing in the Super Bowl? Both involve circumstances that cause the body to involuntarily lose water. Astronauts and athletes with low body water can suffer physical performance impairments and can develop symptoms such as headaches, fatigue, muscle cramps, light headedness, disorientation and, in severe cases, loss of consciousness.

4 Feb 2014

Children newly diagnosed with Crohn's disease may benefit from biologic drugs

Children newly diagnosed with Crohn's disease may benefit from early treatment with the biologic drugs known as anti-TNF-α agents, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.

3 Feb 2014

Researchers identify components of C. diff bacteria that can be used to develop better treatment

Rhode Island Hospital researchers have identified components in Clostridium difficile (C. diff) that may lead to new diagnostic tools, and ultimately more timely and effective treatment for this often fatal infection. C. diff is a spore-forming bacterium that causes severe diarrhea and is responsible for 14,000 deaths annually in the U.S. The study is published online in advance of print in the Journal of Molecular Diagnostics.

31 Jan 2014

Llama-derived antibodies open door to development of new treatments for C. difficile infections

Researchers from the Alberta Glycomics Centre at the University of Calgary and the University of Alberta, in collaboration with researchers at the National Research Council of Canada in Ottawa, have revealed the first molecular views showing how highly specific antibodies derived from llamas may provide a new method for controlling deadly infections from the opportunistic bacterial pathogen Clostridium difficile (C. difficile).

31 Jan 2014

Scientists to develop faster method for pathogen screening in food products

The regular appearance of food poisoning in the news, including a recent event that led to the recall of more than 33,000 pounds of chicken, drives home the need for better bacterial detection long before meats and produce make it to the dinner table.

30 Jan 2014

Researchers identify chemical substance to treat bacterial infections

Increasing numbers of bacteria are developing antibiotic resistance. This forms a significant challenge in the battle against bacterial infections. Alvin Lo and Han Remaut (VIB/Vrije Universiteit Brussel) have identified a chemical substance with the potential of acting as a new drug to treat bacterial infections, particularly urinary tract infections.

29 Jan 2014

Pfizer announces results from Phase 3 study of ALO-02 in patients with chronic low back pain

Pfizer Inc. (NYSE: PFE) announced today top-line results from a Phase 3 study of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic low back pain.

24 Jan 2014

Etoposide plus cisplatin remains best for limited-stage SCLC

Etoposide plus cisplatin, given alongside accelerated hyperfractionated thoracic radiotherapy, remains the gold standard regimen for patients with limited-stage small-cell lung cancer, Japanese researchers say.

23 Jan 2014

New oral drug appears to offer hope for fighting indolent non-Hodgkin lymphoma

Slow-growing, or indolent, non-Hodgkin lymphomas are difficult to treat, with most patients relapsing repeatedly and the disease becoming increasingly resistant to therapy over time.

22 Jan 2014

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

Alexion Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted an orphan drug designation to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of delayed graft function in renal transplant patients.

21 Jan 2014

$Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL$

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval of ADCETRIS (brentuximab vedotin) from the Japanese Ministry of Health, Labour and Welfare for the treatment of patients with CD30-positive relapsed or refractory Hodgkin lymphoma and anaplastic large cell lymphoma.

18 Jan 2014

Diarrhea News and Research

Latest Diarrhea News and Research

FDA grants full approval of SYNRIBO for injection

Researchers offer new options for men whose prostate cancer has spread to bones

Alba Therapeutics reports positive results from Phase IIb trial of larazotide acetate for CeD treatment

Zoetis reports revenue of $1.25 billion for Q4 2013

Mallinckrodt announces commercial launch of PENNSAID

Sarepta Therapeutics reports positive safety results from AVI-7288 Phase I study

Rice, UTMB develop diagnostic test for cryptosporidiosis

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Furiex announces top-line results of Phase III clinical trials of eluxadoline in treatment of IBS-d

Researchers develop rehydration beverage to treat hypohydration in astronauts

Children newly diagnosed with Crohn's disease may benefit from biologic drugs

Researchers identify components of C. diff bacteria that can be used to develop better treatment

Llama-derived antibodies open door to development of new treatments for C. difficile infections

Scientists to develop faster method for pathogen screening in food products

Researchers identify chemical substance to treat bacterial infections

Pfizer announces results from Phase 3 study of ALO-02 in patients with chronic low back pain

Etoposide plus cisplatin remains best for limited-stage SCLC

New oral drug appears to offer hope for fighting indolent non-Hodgkin lymphoma

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

Industry Focus eBook - Pharmaceutical manufacturing (2nd edition) eBook

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Diarrhea News and Research

Latest Diarrhea News and Research

Industry Focus eBook - Pharmaceutical manufacturing (2nd edition) eBook

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Newsletters you may be interested in